UA74648C2 - Disintegration means for dry powder inhalers and inhaler itself - Google Patents

Disintegration means for dry powder inhalers and inhaler itself Download PDF

Info

Publication number: UA74648C2
Authority: UA; Ukraine
Prior art keywords: chamber; particles; air; flow; carrier
Prior art date: 2001-06-22

Application number

UA20031211618A

Other languages

English (en)

Ukrainian (uk)

Inventor

Anne Haaije De Boer

Henderik Willem Frijlink

Original Assignee

Sofotech Gmbx & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-22

Filing date

2002-06-15

Publication date

2006-01-16

2002-06-15 Application filed by Sofotech Gmbx & Co Kg filed Critical Sofotech Gmbx & Co Kg

2006-01-16 Publication of UA74648C2 publication Critical patent/UA74648C2/uk

Links

239000000843 powder Substances 0.000 title abstract description 128
239000002245 particle Substances 0.000 abstract description 253
239000000203 mixture Substances 0.000 abstract description 128
238000000034 method Methods 0.000 abstract description 9
238000009472 formulation Methods 0.000 abstract 1
239000003814 drug Substances 0.000 description 110
229940079593 drug Drugs 0.000 description 102
239000008187 granular material Substances 0.000 description 61
239000010419 fine particle Substances 0.000 description 51
238000013461 design Methods 0.000 description 50
230000014759 maintenance of location Effects 0.000 description 47
239000000853 adhesive Substances 0.000 description 46
230000001070 adhesive effect Effects 0.000 description 46
239000013078 crystal Substances 0.000 description 41
238000000926 separation method Methods 0.000 description 27
230000000694 effects Effects 0.000 description 23
210000000214 mouth Anatomy 0.000 description 23
239000000243 solution Substances 0.000 description 22
238000002156 mixing Methods 0.000 description 21
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 20
239000002775 capsule Substances 0.000 description 20
210000004027 cell Anatomy 0.000 description 19
230000009471 action Effects 0.000 description 17
229960001375 lactose Drugs 0.000 description 17
239000008101 lactose Substances 0.000 description 17
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 16
238000005054 agglomeration Methods 0.000 description 16
230000002829 reductive effect Effects 0.000 description 16
239000000443 aerosol Substances 0.000 description 15
230000002776 aggregation Effects 0.000 description 15
210000003800 pharynx Anatomy 0.000 description 13
230000009467 reduction Effects 0.000 description 13
230000008901 benefit Effects 0.000 description 12
230000003993 interaction Effects 0.000 description 12
230000036961 partial effect Effects 0.000 description 12
238000010276 construction Methods 0.000 description 11
230000006870 function Effects 0.000 description 11
239000000463 material Substances 0.000 description 11
238000012986 modification Methods 0.000 description 11
210000002345 respiratory system Anatomy 0.000 description 11
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 10
229960004436 budesonide Drugs 0.000 description 10
238000010586 diagram Methods 0.000 description 10
230000004048 modification Effects 0.000 description 10
230000001133 acceleration Effects 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000000969 carrier Substances 0.000 description 8
230000006378 damage Effects 0.000 description 8
230000008021 deposition Effects 0.000 description 8
238000005755 formation reaction Methods 0.000 description 8
230000000717 retained effect Effects 0.000 description 8
238000009825 accumulation Methods 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000007423 decrease Effects 0.000 description 7
239000006185 dispersion Substances 0.000 description 7
238000009826 distribution Methods 0.000 description 7
238000011068 loading method Methods 0.000 description 7
238000005259 measurement Methods 0.000 description 7
239000011505 plaster Substances 0.000 description 7
238000003860 storage Methods 0.000 description 7
238000010408 sweeping Methods 0.000 description 7
230000008859 change Effects 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
239000011164 primary particle Substances 0.000 description 6
238000004062 sedimentation Methods 0.000 description 6
108010078777 Colistin Proteins 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
238000013459 approach Methods 0.000 description 5
230000004888 barrier function Effects 0.000 description 5
238000005520 cutting process Methods 0.000 description 5
238000000227 grinding Methods 0.000 description 5
125000006850 spacer group Chemical group 0.000 description 5
229930195727 α-lactose Natural products 0.000 description 5
239000012876 carrier material Substances 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
238000006073 displacement reaction Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000945 filler Substances 0.000 description 4
230000005484 gravity Effects 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000021715 photosynthesis, light harvesting Effects 0.000 description 4
230000035939 shock Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
230000007704 transition Effects 0.000 description 4
206010007134 Candida infections Diseases 0.000 description 3
206010013952 Dysphonia Diseases 0.000 description 3
208000010473 Hoarseness Diseases 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
239000013543 active substance Substances 0.000 description 3
238000012387 aerosolization Methods 0.000 description 3
201000003984 candidiasis Diseases 0.000 description 3
238000004140 cleaning Methods 0.000 description 3
229960001127 colistin sulfate Drugs 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
230000007547 defect Effects 0.000 description 3
229940112141 dry powder inhaler Drugs 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000006260 foam Substances 0.000 description 3
239000012634 fragment Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000007794 irritation Effects 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
230000007774 longterm Effects 0.000 description 3
ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 3
238000005457 optimization Methods 0.000 description 3
238000005192 partition Methods 0.000 description 3
239000011148 porous material Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
238000007790 scraping Methods 0.000 description 3
241000222122 Candida albicans Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
229960003346 colistin Drugs 0.000 description 2
239000004567 concrete Substances 0.000 description 2
238000012937 correction Methods 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000011888 foil Substances 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000003434 inspiratory effect Effects 0.000 description 2
230000010354 integration Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 2
XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
238000005096 rolling process Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
210000004243 sweat Anatomy 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000004804 winding Methods 0.000 description 2
FHYAUNJNVMGZQN-NHCUHLMSSA-N (2r,3r)-5-iodo-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1CN([C@@H]2CC3=C(I)C=CC=C3C[C@H]2O)CCC1C1=CC=CC=C1 FHYAUNJNVMGZQN-NHCUHLMSSA-N 0.000 description 1
SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
241001674044 Blattodea Species 0.000 description 1
244000293889 Bombax malabaricum Species 0.000 description 1
235000004480 Bombax malabaricum Nutrition 0.000 description 1
241000283707 Capra Species 0.000 description 1
244000037364 Cinnamomum aromaticum Species 0.000 description 1
235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
241000272470 Circus Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
244000182067 Fraxinus ornus Species 0.000 description 1
235000002917 Fraxinus ornus Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101000702691 Homo sapiens Zinc finger protein SNAI1 Proteins 0.000 description 1
241000030781 Ippa Species 0.000 description 1
244000208060 Lawsonia inermis Species 0.000 description 1
206010051602 Laziness Diseases 0.000 description 1
241000283965 Ochotona princeps Species 0.000 description 1
206010068319 Oropharyngeal pain Diseases 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
244000007853 Sarothamnus scoparius Species 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
206010049633 Shoshin beriberi Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
238000005411 Van der Waals force Methods 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
102100030917 Zinc finger protein SNAI1 Human genes 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
-1 alpha-lactose monohydrogen Chemical class 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000002528 anti-freeze Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
238000003287 bathing Methods 0.000 description 1
238000005452 bending Methods 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000037182 bone density Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
210000004081 cilia Anatomy 0.000 description 1
239000011362 coarse particle Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003640 drug residue Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005265 energy consumption Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
210000000887 face Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000004992 fission Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000005242 forging Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
210000003128 head Anatomy 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
239000012535 impurity Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000001788 irregular Effects 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960001664 mometasone Drugs 0.000 description 1
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
238000000465 moulding Methods 0.000 description 1
BNGZNZUNROGDHT-UHFFFAOYSA-N n-[4-oxo-2-(2h-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide;hydrate Chemical compound O.C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC1=CC=CC(C(C=2)=O)=C1OC=2C=1N=NNN=1 BNGZNZUNROGDHT-UHFFFAOYSA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000010355 oscillation Effects 0.000 description 1
238000010951 particle size reduction Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000001814 pectin Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006069 physical mixture Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229960004583 pranlukast Drugs 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
208000023804 progressive myoclonic epilepsy type 7 Diseases 0.000 description 1
KKMLIVYBGSAJPM-UHFFFAOYSA-L propineb Chemical compound [Zn+2].[S-]C(=S)NC(C)CNC([S-])=S KKMLIVYBGSAJPM-UHFFFAOYSA-L 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
229960005018 salmeterol xinafoate Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000010008 shearing Methods 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
229940126589 solid medicine Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000004575 stone Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000003746 surface roughness Effects 0.000 description 1
230000002522 swelling effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
208000023409 throat pain Diseases 0.000 description 1
238000004448 titration Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
229960001296 zinc oxide Drugs 0.000 description 1
XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc oxide Inorganic materials [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
235000014692 zinc oxide Nutrition 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1
229930195724 β-lactose Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Anesthesiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Detergent Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA20031211618A 2001-06-22 2002-06-15 Disintegration means for dry powder inhalers and inhaler itself UA74648C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10129703A DE10129703A1 (de)	2001-06-22	2001-06-22	Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
PCT/EP2002/006610 WO2003000325A1 (fr)	2001-06-22	2002-06-15	Systeme de desintegration de formulation de poudre et procede pour inhalateurs de poudre seche

Publications (1)

Publication Number	Publication Date
UA74648C2 true UA74648C2 (en)	2006-01-16

Family

ID=7688810

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20031211618A UA74648C2 (en)	2001-06-22	2002-06-15	Disintegration means for dry powder inhalers and inhaler itself

Country Status (30)

Country	Link
EP (1)	EP1397174B1 (fr)
JP (1)	JP4116537B2 (fr)
KR (1)	KR100904955B1 (fr)
CN (1)	CN100337699C (fr)
AR (1)	AR034616A1 (fr)
AT (1)	ATE477826T1 (fr)
AU (1)	AU2009200071B2 (fr)
BG (1)	BG66589B1 (fr)
BR (2)	BRPI0210026B8 (fr)
CA (1)	CA2445892C (fr)
CY (1)	CY1110924T1 (fr)
CZ (1)	CZ302528B6 (fr)
DE (2)	DE10129703A1 (fr)
DK (1)	DK1397174T3 (fr)
ES (1)	ES2350973T3 (fr)
HR (1)	HRP20040058B1 (fr)
HU (1)	HU227457B1 (fr)
IL (3)	IL158614A0 (fr)
MX (1)	MXPA03011550A (fr)
NO (1)	NO332992B1 (fr)
NZ (1)	NZ530308A (fr)
PL (1)	PL204900B1 (fr)
PT (1)	PT1397174E (fr)
RU (1)	RU2291717C2 (fr)
SI (1)	SI1397174T1 (fr)
SK (1)	SK288034B6 (fr)
TW (1)	TW567075B (fr)
UA (1)	UA74648C2 (fr)
WO (1)	WO2003000325A1 (fr)
ZA (1)	ZA200308555B (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1488819A1 (fr)	2003-06-16	2004-12-22	Rijksuniversiteit te Groningen	Inhalateur de poudre sèche et procédé d'inhalation pulmonaire de poudre sèche
RU2258539C1 (ru) *	2004-03-23	2005-08-20	Чучалин Александр Григорьевич	Порошковый ингалятор
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
DE102005046645B3 (de) *	2005-09-29	2006-07-20	Braunform Gmbh	Pulverinhalator
DE102005046644B3 (de) *	2005-09-29	2006-07-20	Braunform Gmbh	Pulverinhalator
DE102006007495A1 (de) *	2006-02-17	2007-08-23	Siegfried Generics International Ag	Dispergiereinheit
WO2007118490A1 (fr) *	2006-04-13	2007-10-25	Boehringer Ingelheim Microparts Gmbh	Distributeur
ES2319596B1 (es)	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
EP2011538B1 (fr) *	2007-07-06	2016-02-17	Vectura Delivery Devices Limited	Inhalateur
EP2020249A1 (fr)	2007-08-01	2009-02-04	Boehringer Ingelheim Pharma GmbH & Co. KG	Inhalateur
UY31272A1 (es)	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
DE102007041720A1 (de) *	2007-09-04	2009-03-05	Alfred Von Schuckmann	Vorrichtung zur Darreichung eines blisterverpackten Medikaments
US8439033B2 (en) *	2007-10-09	2013-05-14	Microdose Therapeutx, Inc.	Inhalation device
JP5570996B2 (ja)	2007-12-14	2014-08-13	エアロデザインズインコーポレイテッド	エアロゾル化可能な食料品の送達
EP2082769B1 (fr)	2008-01-24	2015-06-03	Vectura Delivery Devices Limited	Inhalateur
EP2082764A1 (fr)	2008-01-24	2009-07-29	Boehringer Ingelheim International GmbH	Inhalateur
EP2100598A1 (fr) *	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2108641A1 (fr)	2008-04-11	2009-10-14	Laboratorios Almirall, S.A.	Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
EP2113503A1 (fr)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	Nouveaux dérivés d'indolin-2-one substitués et leur utilisation comme inhibiteurs de p38 mitogen-activated kinase
CN102036706B (zh) *	2008-05-23	2013-02-27	大塚制药株式会社	粉末吸入器
EP2135610A1 (fr)	2008-06-20	2009-12-23	Laboratorios Almirall, S.A.	Combinaison comportant des inhibiteurs DHODH et de la méthotrexate
EP2177521A1 (fr)	2008-10-14	2010-04-21	Almirall, S.A.	Nouveaux dérivés de 2-amidothiadiazole
EP2196465A1 (fr)	2008-12-15	2010-06-16	Almirall, S.A.	Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4
UY32297A (es)	2008-12-22	2010-05-31	Almirall Sa	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2202232A1 (fr)	2008-12-26	2010-06-30	Laboratorios Almirall, S.A.	Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
EP2210890A1 (fr)	2009-01-19	2010-07-28	Almirall, S.A.	Dérivés d'oxadiazoles en tant qu'agonistes du récepteur S1P1
EP2210615A1 (fr)	2009-01-21	2010-07-28	Almirall, S.A.	Combinaisons comportant des inhibiteurs DHODH et de la méthotrexate
EP2221055A1 (fr)	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one pour le traitement de la fonction pulmonaire
EP2221297A1 (fr)	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one et son utiisation dans le traitement de maladies des voies respiratoires
EP2226323A1 (fr)	2009-02-27	2010-09-08	Almirall, S.A.	Nouveaux dérivés de tétrahydropyrazolo [3,4-c]isoquinoléine-5-amine
MX2011009251A (es) *	2009-03-04	2011-11-18	Mannkind Corp	Sistema mejorado de suministro de farmaco en polvo seco.
EP2228368A1 (fr)	2009-03-12	2010-09-15	Almirall, S.A.	Procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-ph2nyl2thoxy)hexyl]amino}-1-hydroxy2thyl)-8-hydroxyquinolin-2(1h)-one
EP2239256A1 (fr)	2009-03-13	2010-10-13	Almirall, S.A.	Sel de sodium de l'acide 5-cyclopropyl-2-{[2-(2,6-difluorophényl)pyrimidin-5-yl]amino}benzoïque en tant qu'inhibiteurs de la DHOD
EP2305660A1 (fr)	2009-09-25	2011-04-06	Almirall, S.A.	Nouveaux dérivés de thiadiazole
EP2314577A1 (fr)	2009-10-16	2011-04-27	Almirall, S.A.	Procédé de fabrication de l'acide 2-[(3,5-difluoro-3'-méthoxy-1,1'-biphényl-4-yl)amino]nicotinique
GB0919465D0 (en) *	2009-11-06	2009-12-23	Norton Healthcare Ltd	Airflow adaptor for a breath-actuated dry powder inhaler
EP2322176A1 (fr)	2009-11-11	2011-05-18	Almirall, S.A.	Nouveaux dérivés de 7-phényl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
AU2010319681B2 (en) *	2009-11-13	2015-12-17	Merck Sharp & Dohme Llc	Drug products, dry powder inhalers and polyflux collider arrangements
EP2343287A1 (fr)	2009-12-10	2011-07-13	Almirall, S.A.	Nouveaux dérivés de 2-aminothiadiazole
EP2338888A1 (fr)	2009-12-24	2011-06-29	Almirall, S.A.	Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
EP2360158A1 (fr)	2010-02-18	2011-08-24	Almirall, S.A.	Dérivés de pyrazole en tant qu'inhibiteurs de JAK
EP2366702A1 (fr)	2010-03-18	2011-09-21	Almirall, S.A.	Nouveaux dérivés d'oxadiazole
EP2380890A1 (fr)	2010-04-23	2011-10-26	Almirall, S.A.	Nouveaux dérivés de 7,8-dihydro-1,6-naphthyridin-5(6h)-one comme PDE4 inhibiteurs
EP2386555A1 (fr)	2010-05-13	2011-11-16	Almirall, S.A.	Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
EP2390252A1 (fr)	2010-05-19	2011-11-30	Almirall, S.A.	Nouveaux dérivés de pyrazole
EP2394998A1 (fr)	2010-05-31	2011-12-14	Almirall, S.A.	Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4
EP2397482A1 (fr)	2010-06-15	2011-12-21	Almirall, S.A.	Dérivés d'imidazolone d'hétéroaryle en tant qu'inhibiteurs de JAK
EP2441755A1 (fr)	2010-09-30	2012-04-18	Almirall, S.A.	Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK
EP2455080A1 (fr)	2010-11-23	2012-05-23	Almirall, S.A.	Agonistes de récepteur S1P1 à utiliser dans le traitement de la sclérose en plaques
EP2455081A1 (fr)	2010-11-23	2012-05-23	Almirall, S.A.	Agonistes de récepteur S1P1 à utiliser dans le traitement de la maladie de Crohn
EP2457900A1 (fr)	2010-11-25	2012-05-30	Almirall, S.A.	Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
EP2463289A1 (fr)	2010-11-26	2012-06-13	Almirall, S.A.	Dérivés imidazo[1,2-b]pyridazine en tant qu'inhibiteur JAK
US8974450B2 (en)	2011-02-03	2015-03-10	Covidien Lp	System and method for ablation procedure monitoring using electrodes
EP2489663A1 (fr)	2011-02-16	2012-08-22	Almirall, S.A.	Composés en tant qu'inhibiteurs de la syk kinase
EP2510928A1 (fr)	2011-04-15	2012-10-17	Almirall, S.A.	Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
EP2518070A1 (fr)	2011-04-29	2012-10-31	Almirall, S.A.	Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K
EP2518071A1 (fr)	2011-04-29	2012-10-31	Almirall, S.A.	Dérivés d'imidazopyridine en tant qu'inhibiteurs PI3K
EP2527344A1 (fr)	2011-05-25	2012-11-28	Almirall, S.A.	Dérivés de pyridin-2(1h)-one utiles comme médicaments pour le traitement de maladies myeloproliferatives, de rejets de greffe, de maladies a médiation immune et de maladies inflammatoires
EP2526945A1 (fr)	2011-05-25	2012-11-28	Almirall, S.A.	Nouveaux antagonistes de CRTH2
EP2548863A1 (fr)	2011-07-18	2013-01-23	Almirall, S.A.	Nouveaux antagonistes de CRTH2
EP2548876A1 (fr)	2011-07-18	2013-01-23	Almirall, S.A.	Nouveaux antagonistes de CRTH2
EP2554544A1 (fr)	2011-08-01	2013-02-06	Almirall, S.A.	Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
CN106730186B (zh)	2011-09-07	2020-06-09	康森特里克斯药物公司	干粉吸入装置
EP2578570A1 (fr)	2011-10-07	2013-04-10	Almirall, S.A.	Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
EP2592078A1 (fr)	2011-11-11	2013-05-15	Almirall, S.A.	Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
EP2592077A1 (fr)	2011-11-11	2013-05-15	Almirall, S.A.	Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
EP2617449A1 (fr) *	2012-01-20	2013-07-24	Almirall S.A.	Dispositif d'inhalation pour médicaments en poudre
EP2617448A1 (fr)	2012-01-20	2013-07-24	Almirall S.A.	Dispositif d'inhalation pour médicaments en poudre
EP2617450A1 (fr)	2012-01-20	2013-07-24	Almirall S.A.	Dispositif d'inhalation pour médicaments en poudre
EP2641900A1 (fr)	2012-03-20	2013-09-25	Almirall, S.A.	Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
EP2647627A1 (fr)	2012-04-02	2013-10-09	Almirall, S.A.	Sels de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phényléthoxy)phényl]éthyl}amino)- 1-hydroxyéthyl]-8- hydroxyquinolin-2(1h)-one
EP2666465A1 (fr)	2012-05-25	2013-11-27	Almirall, S.A.	Nouveau dosage et formule
EP2668941A1 (fr)	2012-05-31	2013-12-04	Almirall, S.A.	Nouveau dosage et formulation d'abediterol
WO2014060431A1 (fr)	2012-10-16	2014-04-24	Almirall, S.A.	Dérivés de pyrrolotriazinone en tant qu'inhibiteurs des pi3k
EP2738172A1 (fr)	2012-11-28	2014-06-04	Almirall, S.A.	Nouveaux composés bicycliques utilisés comme modulateurs du canal crac
PL2931275T3 (pl)	2012-12-17	2022-09-05	Almirall S.A.	Aklidyna do zastosowania w zwiększaniu aktywności fizycznej w codziennym życiu u pacjenta z przewlekłą obturacyjną chorobą płuc
BR112015013628A2 (pt)	2012-12-18	2017-07-11	Almirall Sa	derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
AR094797A1 (es)	2013-02-15	2015-08-26	Almirall Sa	Derivados de pirrolotriazina como inhibidores de pi3k
EP2848615A1 (fr)	2013-07-03	2015-03-18	Almirall, S.A.	Nouveaux dérivés de pyrazole utilisés comme modulateurs du canal CRAC
WO2015091287A1 (fr)	2013-12-19	2015-06-25	Almirall S.A.	Formulation pharmaceutique comprenant du salmétérol et du propionate de fluticasone
EP2944343A1 (fr)	2014-05-15	2015-11-18	AstraZeneca AB	Inhalateur de poudre sèche
WO2015187025A1 (fr) *	2014-06-06	2015-12-10	Rijksuniversiteit Groningen	Inhalateur à poudre sèche actionné par la respiration
EP3223891B1 (fr)	2014-11-26	2018-09-05	Vectura Delivery Devices Limited	Dispositif d'ouverture pour blysters utilisé dans un inhalateur de poudre sèche
JP2018501903A (ja)	2015-01-14	2018-01-25	レスピラセラピューティクスインコーポレイテッドＲｅｓｐｉｒａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	パウダー分散方法および装置
EP3286178A1 (fr)	2015-04-21	2018-02-28	Almirall S.A.	Dérivés hétérocycliques amino-substitués utilisés comme inhibiteurs des canaux sodiques
WO2016202800A1 (fr)	2015-06-16	2016-12-22	Almirall, S.A.	Dérivés de pyrrolotriazinone en tant qu'inhibiteurs de pi3k
WO2017076990A1 (fr)	2015-11-05	2017-05-11	Almirall, S.A.	Sels d'addition de n-[4-(4-{[(1s)-1-(5-méthyl-4-oxo-3-phényl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)éthyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide
RU2634258C1 (ru) *	2016-11-08	2017-10-24	федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН)	Наполнитель для капсульного ингалятора
WO2018100462A1 (fr) *	2016-11-30	2018-06-07	Philip Morris Products S.A.	Inhalateur à cavité dimensionnée
CN110494181B (zh)	2017-03-28	2022-03-18	康森特里克斯药物公司	用于输送干粉药物的装置和方法
CN107123354B (zh) *	2017-05-21	2019-03-19	谭淞文	分选花形微粒载体的吸入器、呼吸道及肺部模型设备集成
TW201919682A (zh)	2017-08-08	2019-06-01	西班牙商阿爾米雷爾有限公司	活化Ｎｒｆ２路徑的新穎化合物
EP3755167B1 (fr) *	2018-02-19	2022-10-19	Philip Morris Products S.A.	Inhalateur de poudre sèche
CN110201280B (zh) *	2018-02-28	2021-07-30	张江	用于吸入给药装置的吸嘴和吸入给药装置
CN110201279B (zh) *	2018-02-28	2021-05-11	张江	用于吸入给药的药盒和吸入给药组合结构
CN110201281B (zh) *	2018-02-28	2021-08-06	张江	吸入给药装置和吸入给药组合结构
CN110201278B (zh) *	2018-02-28	2021-07-30	张江	用于吸入给药的药盒和吸入给药组合结构
CN111514418B (zh) *	2019-06-12	2022-01-14	中南大学湘雅二医院	一种自吸式经鼻粉末材料给送装置
CN111359060A (zh) *	2020-02-20	2020-07-03	深圳麦克韦尔科技有限公司	雾化吸嘴及雾化装置
US12117379B2 (en) *	2020-05-15	2024-10-15	Horiba, Ltd.	Sample dispersing device and sample dispersing method
CN112030136B (zh) *	2020-09-01	2024-12-27	江苏微导纳米科技股份有限公司	镀膜腔体及粉末镀膜装置
CN113750331B (zh) *	2021-08-18	2022-08-16	华中科技大学	一种干粉吸入器
CN114632235B (zh) *	2022-03-04	2023-04-25	华中科技大学	一种干粉吸入器
CN115006656A (zh) *	2022-05-18	2022-09-06	苏州易合医药有限公司	一种可连续提供肺部活性剂粉雾剂的给药装置
CN117547693B (zh) *	2023-12-20	2025-08-01	上海新黄河制药有限公司	一种适用于双储库粉雾剂装置的流道

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1478138A (en) *	1973-07-18	1977-06-29	Beecham Group Ltd	Device for the administration of powders
IT7920688U1 (it)	1979-02-05	1980-08-05	Chiesi Paolo	Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
CY1492A (en)	1981-07-08	1990-02-16	Draco Ab	Powder inhalator
US4570630A (en)	1983-08-03	1986-02-18	Miles Laboratories, Inc.	Medicament inhalation device
DE3927170A1 (de)	1989-08-17	1991-02-21	Boehringer Ingelheim Kg	Inhalator
IT1237118B (it)	1989-10-27	1993-05-18	Miat Spa	Inalatore multidose per farmaci in polvere.
NZ238489A (en) *	1990-06-14	1995-09-26	Rhone Poulenc Rorer Ltd	Inhaler with capsule in swirling chamber: capsule pierced in chamber
WO1992003175A1 (fr)	1990-08-11	1992-03-05	Fisons Plc	Dispositif d'inhalation
US5492112A (en) *	1991-05-20	1996-02-20	Dura Pharmaceuticals, Inc.	Dry powder inhaler
DE4211475A1 (de) *	1991-12-14	1993-06-17	Asta Medica Ag	Pulverinhalator
DE4239402A1 (de) *	1992-11-24	1994-05-26	Bayer Ag	Pulverinhalator
WO1994014492A2 (fr)	1992-12-18	1994-07-07	Schering Corporation	Inhalateur pour medicaments en poudre
WO1996010459A2 (fr) *	1994-10-04	1996-04-11	Imperial Chemical Industries Plc	Pulverisation electrostatique de matiere particulaire
DE19522416C2 (de) *	1995-06-21	2003-11-20	Sofotec Gmbh & Co Kg	Vorrichtung zum Dispergieren von Pulver in einem Luftstrom zur Verwendung mit Pulver-Inhalatoren
IL122494A (en) *	1995-06-21	2001-08-08	Asta Medica Ag	A cartridge for pharmaceutical powder with a measuring device and an integral inhaler for powdered medicines
FR2738153B1 (fr) *	1995-09-04	1998-01-02	Valois	Appareil d'inhalation destine a distribuer des doses precises et reproductibles de produit pulverulent
EP1129705A1 (fr) *	2000-02-17	2001-09-05	Rijksuniversiteit te Groningen	Formulation en poudre pour inhalation

2001
- 2001-06-22 DE DE10129703A patent/DE10129703A1/de not_active Withdrawn
2002
- 2002-06-12 TW TW091112804A patent/TW567075B/zh not_active IP Right Cessation
- 2002-06-15 NZ NZ530308A patent/NZ530308A/en not_active IP Right Cessation
- 2002-06-15 HU HU0400212A patent/HU227457B1/hu unknown
- 2002-06-15 CN CNB02812121XA patent/CN100337699C/zh not_active Expired - Lifetime
- 2002-06-15 BR BRPI0210026A patent/BRPI0210026B8/pt not_active IP Right Cessation
- 2002-06-15 MX MXPA03011550A patent/MXPA03011550A/es active IP Right Grant
- 2002-06-15 WO PCT/EP2002/006610 patent/WO2003000325A1/fr active Application Filing
- 2002-06-15 CA CA2445892A patent/CA2445892C/fr not_active Expired - Lifetime
- 2002-06-15 AT AT02780833T patent/ATE477826T1/de active
- 2002-06-15 PL PL365946A patent/PL204900B1/pl unknown
- 2002-06-15 PT PT02780833T patent/PT1397174E/pt unknown
- 2002-06-15 SK SK27-2004A patent/SK288034B6/sk unknown
- 2002-06-15 EP EP02780833A patent/EP1397174B1/fr not_active Expired - Lifetime
- 2002-06-15 UA UA20031211618A patent/UA74648C2/uk unknown
- 2002-06-15 JP JP2003506966A patent/JP4116537B2/ja not_active Expired - Lifetime
- 2002-06-15 KR KR1020037016628A patent/KR100904955B1/ko not_active Expired - Lifetime
- 2002-06-15 DE DE60237366T patent/DE60237366D1/de not_active Expired - Lifetime
- 2002-06-15 ES ES02780833T patent/ES2350973T3/es not_active Expired - Lifetime
- 2002-06-15 IL IL15861402A patent/IL158614A0/xx unknown
- 2002-06-15 CZ CZ20040046A patent/CZ302528B6/cs not_active IP Right Cessation
- 2002-06-15 BR BR0210026-6A patent/BR0210026A/pt active IP Right Grant
- 2002-06-15 HR HRP20040058AA patent/HRP20040058B1/hr not_active IP Right Cessation
- 2002-06-15 DK DK02780833.6T patent/DK1397174T3/da active
- 2002-06-15 SI SI200230925T patent/SI1397174T1/sl unknown
- 2002-06-15 RU RU2004102037/14A patent/RU2291717C2/ru active
- 2002-06-21 AR ARP020102359A patent/AR034616A1/es active IP Right Grant
2003
- 2003-10-27 IL IL158614A patent/IL158614A/en active IP Right Grant
- 2003-11-03 ZA ZA200308555A patent/ZA200308555B/en unknown
- 2003-12-17 NO NO20035654A patent/NO332992B1/no not_active IP Right Cessation
2004
- 2004-01-06 BG BG108512A patent/BG66589B1/bg unknown
2009
- 2009-01-08 AU AU2009200071A patent/AU2009200071B2/en not_active Expired
2010
- 2010-11-17 CY CY20101101039T patent/CY1110924T1/el unknown
2011
- 2011-02-01 IL IL210983A patent/IL210983A/en active IP Right Grant

Also Published As

Publication number	Publication date
SI1397174T1 (sl)	2010-12-31
HUP0400212A2 (en)	2004-06-28
CZ302528B6 (cs)	2011-07-07
AR034616A1 (es)	2004-03-03
NO332992B1 (no)	2013-02-11
IL158614A (en)	2012-12-31
BRPI0210026B8 (pt)	2021-06-22
ES2350973T3 (es)	2011-01-28
DE10129703A1 (de)	2003-01-02
JP4116537B2 (ja)	2008-07-09
NZ530308A (en)	2007-01-26
RU2004102037A (ru)	2005-05-27
PT1397174E (pt)	2010-11-10
PL365946A1 (en)	2005-01-24
EP1397174B1 (fr)	2010-08-18
AU2009200071B2 (en)	2011-07-07
DE60237366D1 (de)	2010-09-30
CA2445892C (fr)	2010-08-10
AU2009200071A1 (en)	2009-02-05
DK1397174T3 (da)	2010-12-06
CY1110924T1 (el)	2015-06-10
MXPA03011550A (es)	2004-03-18
NO20035654D0 (no)	2003-12-17
BRPI0210026B1 (pt)	2018-04-03
BR0210026A (pt)	2004-04-13
KR20040039203A (ko)	2004-05-10
ATE477826T1 (de)	2010-09-15
SK272004A3 (sk)	2005-10-06
CZ200446A3 (cs)	2005-02-16
EP1397174A1 (fr)	2004-03-17
HRP20040058A2 (en)	2004-08-31
SK288034B6 (en)	2013-01-02
BG66589B1 (bg)	2017-07-31
CN1541125A (zh)	2004-10-27
HK1064313A1 (en)	2005-01-28
ZA200308555B (en)	2004-02-17
WO2003000325A1 (fr)	2003-01-03
KR100904955B1 (ko)	2009-06-26
NO20035654L (no)	2004-02-18
CN100337699C (zh)	2007-09-19
RU2291717C2 (ru)	2007-01-20
PL204900B1 (pl)	2010-02-26
CA2445892A1 (fr)	2003-01-03
IL210983A (en)	2014-11-30
IL158614A0 (en)	2004-05-12
IL210983A0 (en)	2011-04-28
JP2004530498A (ja)	2004-10-07
HU227457B1 (en)	2011-06-28
TW567075B (en)	2003-12-21
BG108512A (en)	2005-02-28
HRP20040058B1 (hr)	2015-02-27

Publication	Publication Date	Title
UA74648C2 (en)	2006-01-16	Disintegration means for dry powder inhalers and inhaler itself
US6681768B2 (en)	2004-01-27	Powder formulation disintegrating system and method for dry powder inhalers
EP0477222B1 (fr)	2000-08-16	Dispositif permettant de réaliser une pulvérisation plus efficace d'un médicament pris par inhalation
JP6946363B2 (ja)	2021-10-06	吸入可能な薬剤
HK1064313B (en)	2010-11-12	Powder formulation disintegrating system and dry powder inhalers
AU2002350483A1 (en)	2003-01-08	Powder formulation disintegrating system and method for dry powder
NZ721338B2 (en)	2022-06-28	Inhalable medicaments
HK1228273A1 (en)	2017-11-03	Inhalable medicaments
IT9020332A1 (it)	1991-11-17	Nedocromil sodio particellare con un diametro medio massico compreso tra 5 e 10 micrometri